RxDoctor Payments Data

Manuel Peralta, MD

Family Medicine · Forest, VANPI 1245451194

Payments from drug & device makers

$14,863in general payments, 2019–2025

Across 1,018 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • Amgen$1K
  • Abbott$757
  • plus $6K from 45 others

What the payments were for

  • Food & beverage$14,812100%
  • Education$510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,863 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$317,301
Medicare patients
562
Services billed
9,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$103,373
TrulicityDulaglutide33$77,111
JardianceEmpagliflozin48$69,379
EliquisApixaban62$50,340
JanuviaSitagliptin Phosphate26$30,886
FarxigaDapagliflozin Propanediol24$26,004
BelbucaBuprenorphine Hcl12$22,497
MounjaroTirzepatide16$16,951
LinzessLinaclotide13$16,403
Tresiba Flextouch U-200Insulin Degludec15$14,965
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$8,921
Atorvastatin Calcium758$5,669
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$5,619
Glipizide ErGlipizide247$4,055
Gabapentin124$3,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,088$103,37372 claims
Lilly USA, LLCTrulicity, Mounjaro$674$94,06349 claims
Boehringer IngelheimJardiance$618$69,37948 claims
PfizerEliquis$1,308$50,34062 claims
MerckJanuvia$140$30,88626 claims
AstraZenecaFarxiga, Symbicort$1,362$28,49435 claims
AbbVieLinzess, Synthroid$1,867$18,09949 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Forest

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →